UK clinical-stage cancer drug developer Immodulon has appointed Dr Josefine Roemmler-Zehrer as chief medical officer.
She brings a significant track record of clinical and medical affairs success to Immodulon at a key time as the company prepares to advance IMM-101 into a pivotal trial in pancreatic cancer.
Dr Roemmler-Zehrer has had senior leadership roles at leading pharmaceutical companies including Celgene, Amgen (Nasdaq: AMGN) and Ipsen (Euronext: IPN). She has a proven track record of success in several product development programmes including Celgene’s Abraxane (nab-paclitaxel) in pancreatic cancer and NSCLC and Ipsen’s Cabometyx in renal cell carcinoma and thyroid cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze